



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| <p>(51) International Patent Classification ⁶ : C12Q 1/68, C07H 21/04, C12P 19/34</p> | A1 | <p>(11) International Publication Number: WO 97/32036</p> <p>(43) International Publication Date: 4 September 1997 (04.09.97)</p> |
| <p>(21) International Application Number: PCT/EP97/00911</p> <p>(22) International Filing Date: 25 February 1997 (25.02.97)</p> <p>(30) Priority Data: 96200516.1 28 February 1996 (28.02.96) EP (34) Countries for which the regional or international application was filed: NL et al.</p> <p>(71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): OVYN, Caroline, Louise, Lucienne [BE/BE]; St. Sebastiaanslaan 32, B-8500 Kortrijk (BE). VAN GEMEN, Bob [NL/NL]; Kortakker 14, NL-5283 TD Boxtel (NL). VAN STRIJP, Dianne, Arnoldina, Margaretha, Wilhelmina [NL/NL]; Maastrichtseweg 97, NL-5215 AG Den Bosch (NL).</p> <p>(74) Agent: VAN GENT, Marieke; P.O. Box 20, NL-5340 BH Oss (NL).</p> | <p>(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> | |
| <p>(54) Title: PRIMERS AND PROBES FOR THE AMPLIFICATION, DETECTION AND TYPING OF MYCOPLASMA PNEUMONIAE</p> | | |
| <p>(57) Abstract</p> <p>Disclosed are oligonucleotides that can be used as primers to amplify a region of the 16S rRNA of <i>M. pneumoniae</i>. The amplified RNA can be detected with known probes for <i>M. pneumoniae</i>. However, with specific probes according to the present invention, not only detection of the amplified RNA but also further characterization with respect to the typing <i>M. pneumoniae</i> strains is possible. The primers, probes, methods and kits are especially useful as an aid in the diagnosis of <i>M. pneumoniae</i>.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|------------------------------------------|----|--------------------------|
| AM | Armenia | GB | United Kingdom | MW | Malawi |
| AT | Austria | GE | Georgia | MX | Mexico |
| AU | Australia | GN | Guinea | NE | Niger |
| BB | Barbados | GR | Greece | NL | Netherlands |
| BE | Belgium | HU | Hungary | NO | Norway |
| BF | Burkina Faso | IE | Ireland | NZ | New Zealand |
| BG | Bulgaria | IT | Italy | PL | Poland |
| BJ | Benin | JP | Japan | PT | Portugal |
| BR | Brazil | KE | Kenya | RO | Romania |
| BY | Belarus | KG | Kyrgystan | RU | Russian Federation |
| CA | Canada | KP | Democratic People's Republic of Korea | SD | Sudan |
| CF | Central African Republic | KR | Republic of Korea | SE | Sweden |
| CG | Congo | KZ | Kazakhstan | SG | Singapore |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovakia |
| CM | Cameroon | LR | Liberia | SN | Senegal |
| CN | China | LT | Lithuania | SZ | Swaziland |
| CS | Czechoslovakia | LU | Luxembourg | TD | Chad |
| CZ | Czech Republic | LV | Latvia | TG | Togo |
| DE | Germany | MC | Monaco | TJ | Tajikistan |
| DK | Denmark | MD | Republic of Moldova | TT | Trinidad and Tobago |
| EE | Estonia | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | UG | Uganda |
| FI | Finland | MN | Mongolia | US | United States of America |
| FR | France | MR | Mauritania | UZ | Uzbekistan |
| GA | Gabon | | | VN | Viet Nam |

PRIMERS AND PROBES FOR THE AMPLIFICATION, DETECTION AND TYPING OF *MYCOPLASMA PNEUMONIAE*.

5 The present invention is directed to oligonucleotides that can be used as primers to amplify a region of the 16S rRNA of *Mycoplasma pneumoniae*. The amplified RNA can be detected with known probes for *M. pneumoniae*. However, with specific probes according to the present invention, not only detection of the amplified RNA but also further characterization with respect to the typing of *M. pneumoniae* strains is possible.

10 The primers, probes, methods and kits are especially useful as an aid in the diagnosis of *M. pneumoniae*.

15 *Mycoplasma pneumoniae* is the causative agent of primary atypical pneumonia and is also responsible for other respiratory syndromes such as bronchitis, bronchiolitis, pharyngitis, croup and less severe upper respiratory tract infections with the highest incidence among school children.

20 Current methods for the diagnosis of *M. pneumoniae* infection include isolation of the organisms on complex media or demonstration of seroconversion during convalescent phases of infection (Leith *et al.*, J. Exp. Med. 157:502-514 (1983)). The mycoplasmas, such as *Mycoplasma pneumoniae*, are fastidious organisms, requiring complex culture media containing peptone, yeast extract, expensive animal sera, and sterol. Growth is relatively slow and reaches low cell densities compared to most bacteria. In addition, atmospheric conditions for cell growth requires the addition of carbon dioxide. For these reasons, many clinical
25 laboratories are unable to perform culture isolation of *M. pneumoniae*, and consequently are left with no real ability to diagnose the presence of this important pathogenic bacterium. Given that mycoplasmas lack cell walls, antibiotics that target the bacterial cell wall, such as penicillin, have no anti-mycoplasma activity. Consequently, it is of importance for a physician to make a diagnosis of atypical
30 pneumonia and prescribe the appropriate antibiotic. Initiation of appropriate therapy cannot be based on culture or serology.

Detection of genomic sequences have been proposed as rapid and specific alternatives. Different PCRs for the detection of *M. pneumoniae* have been described, using as targets the gene coding for the P1 adhesion protein (Jensen *et al.*, Acta Pathol. Microbiol. Immunol. Scand. 97:1046-1048 (1989); Ursi *et al.*, Acta Pathol. Microbiol. Immunol. Scand. 100:635-639 (1992)) or the 16S rRNA gene (van Kuppeveld *et al.*, Appl. Environ. Microbiol. 58:2606-2615 (1992)) or a DNA sequence specific for *M. pneumoniae* selected from a genomic library (Bernet *et al.*, J. Clin. Microbiol., 27:2492-2496 (1989)).

40 Although these methods have lesser drawbacks than culturing and serology, they are still too complex to be carried out in a routine diagnostic laboratory. False negative PCR results are rather common due to inhibitors of the PCR reaction in the

clinical specimen, while false-positive results may occur due to contamination of the reagents with target DNA (Razin, Mol. and Cell. Probes, 8, 497-511 (1994)).

Based on sequence divergency of the major cytoadhesin gene P1 (Su *et al.*, Infect. Immun. **58**:2669-2674 (1990)), restriction enzyme fingerprinting of genomic DNA (Su *et al.*, J. Gen. Microbiol. **137**:2727-2732 (1991); Su *et al.*, J. Clin. Microbiol. **28**:1538-1540 (1990)), two-dimensional gel electrophoresis of total proteins and PCR-mediated DNA fingerprinting (Ursi *et al.*, J. Clin. Microbiol. **32**:2873-2875 (1994)), only two types are presently recognized, indicating that *M. pneumoniae* as a species is genetically remarkably stable.

It was suggested by Ursi and coworkers that a switch in time from one type to another could be explained by the immunestatus of the population against one of these two types.

Typing *M. pneumoniae* is of major importance because unambiguous characterization is the basis for further identification of *M. pneumoniae* strains. Studies based on virulence differences between one strain to the other strain could be based on type-specificity. Furthermore, a relation may exist between type and sensitivity to antibiotics like macrolides and tetracyclines. Also the spread of *M. pneumoniae* strains could be studied based on type differences. The prevalence of both types seems to be time and geographic dependent.

M. pneumoniae has a very small genome of approximately 720-750 kb. In Mycoplasmal 16S ribosomal RNA, there are regions with highly conserved sequences and variable regions, V1 to V9, according to the nomenclature of Neefs *et al.* (Nucleic Acids Res. **18** suppl:2237-2317 (1990)).

Ribosomes are of profound importance to all organisms because they serve as the only known means of translating genetic information into cellular proteins, the main structural and catalytic elements of life. A clear manifestation of this importance is the observation that all cells have ribosomes.

Bacterial ribosomes contain three distinct RNA molecules which, at least in *Escherichia coli*, are referred to as 5S, 16S and 23S rRNAs. In eukaryotic organisms, there are four distinct rRNA species, generally referred to as 5S, 18S, 28S, and 5.8S. These names historically are related to the size of the RNA molecules, as determined by their sedimentation rate. In actuality, however, ribosomal RNA molecules vary substantially in size between organisms. Nonetheless, 5S, 16S, and 23S rRNA are commonly used as generic names for the homologous RNA molecules in any bacterium, including the mycoplasmas, and this convention will be continued herein.

An amplification system that has significant advantages over PCR amplification systems is the amplification system referred to as NASBA® (nucleic

acid sequence-based amplification). The NASBA® methodology is disclosed in European Patent No. 0 329 822 B1. As compared to PCR, NASBA® requires less user participation and fewer manipulations and steps. Another advantage is that NASBA® is performed at a relatively constant temperature, ensuring that the enzymes used in the process do not lose their activity. Finally, in NASBA® each cycle of the amplification process generates a plurality of RNA copies from one substrate. Therefore, it is considered preferable to use the NASBA® system to amplify mycoplasmal RNA, which in turn can be detected using nucleic acid probes.

NASBA® is an enzymatic process for the amplification of RNA. Four enzyme activities are required: RNA-directed DNA-polymerase, DNA-directed DNA-polymerase, RNase H and DNA-directed RNA-polymerase. The first three activities can be provided by reverse transcriptase (preferably avian myoblastosis virus reverse transcriptase (AMV-RT)), the fourth one preferably by T7 RNA-polymerase. For optimum amplification, more RNase H activity than provided by the AMV-RT can be desirable, in which case additional enzyme (e.g. *E. coli* RNase H) can be added to the reaction. The first step in NASBA® consists of specific hybridization of a DNA primer to the RNA target followed by cDNA synthesis by RT. RNase H activity and annealing of a second primer allow synthesis of double-stranded DNA. One (or both) of the primers contain, in addition to target-specific hybridization sequences, an RNA polymerase promoter sequence (preferably for T7 RNA polymerase). Formation of a double-stranded RNA polymerase promoter suffices to initiate transcription by RNA-polymerase, resulting in multiple copies of the complementary RNA sequence (complementary to the original RNA sequence), which in turn can serve as target for a new round of NASBA® amplification.

Variations in the NASBA® method are considered within the scope of the present invention. For instance, one may use 'destabilizing' nucleotide triphosphates in the amplification, such as ionosine triphosphate disclosed in European patent application No. 92.202.564.8, published in 1994. In addition, it is not necessary to use RNase H, as a separate enzyme, in the NASBA® reaction, because it is known in the art that reverse transcriptase itself has RNase H activity under appropriate conditions, as disclosed by Sambrook *et al.*, Molecular Cloning (1993). Other variations would be apparent to those skilled in the art.

The NASBA® technique applied can be followed by a detection method like 'in solution' hybridization in an enzyme-linked gel assay (ELGA) disclosed in United States Patent No. 5,482,832. However, other methods can also be applied.

As in any amplification system, one must find suitable primers to amplify the sequence of interest. The need therefore exists for primer sets and hybridization probes that can be used for the amplification and subsequent detection of Mycoplasmata, particularly *Mycoplasma pneumoniae*.

The present invention is directed to oligonucleotides to be used as primers for amplification of *M. pneumoniae* 16S ribosomal RNA preferably by the NASBA® system. These primers, which can be completely described by chemical composition and structure, are single stranded DNA. A pair of primers, with each individual primer being unique, is required in the NASBA® system.

The sensitivity and reliability of *M. pneumoniae* nucleic acid sequence detection is greatly dependent on primer selection, since there is sequence variation among strains of *M. pneumoniae*. Ideally, primer selection should be based on knowledge of interstrain variability in candidate primer sequences and the consequences of mismatching at primer sites. (Chou S., J. of Clin. Microbiol., 2307-2310 (1992)).

The need therefore exists for suitable oligonucleotides including nucleic acid sequences that can be used as primers and hybridization-probes for the amplification and subsequent detection of all strain variants of *M. pneumoniae*.

The binding sites of preferred primers according to the present invention are located in a highly conserved region and a variable region (V2) of 16S ribosomal RNA.

An object of the present invention is an oligonucleotide, 10-35 nucleotides in length comprising, at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:

(P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3',
(P2) 5' GAT CCT GGC TCA GGA TTA A 3', or
its complementary sequence.

A preferred embodiment of the oligonucleotide according to the present invention is an oligonucleotide operably linked to a promoter nucleic acid sequence like T7 RNA polymerase with sequence 5' AAT TCT AAT ACG ACT CAC TAT AGG G 3'.

Another object of the present invention is a pair of oligonucleotide primers for the amplification of *Mycoplasma pneumoniae* nucleic acid comprising oligonucleotides consisting essentially of the following nucleic acid sequences:

(P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3',
(P2) 5' GAT CCT GGC TCA GGA TTA A 3', optionally linked to a promoter nucleic acid sequence.

The term "oligonucleotide" as used herein refers to a molecule comprising two or more deoxyribonucleotides or ribonucleotides such as primers and probes.

The oligonucleotides according to the present invention are highly suitable for use as primers in amplification reactions for the amplification, and subsequent detection, of mycoplasmal nucleic acid.

5 The term "primer" as used herein refers to an oligonucleotide either naturally occurring (e.g. as a restriction fragment) or produced synthetically, which is capable of acting as a point of initiation of synthesis of a primer extension product which is complementary to a nucleic acid strand (template or target sequence) when placed under suitable conditions (e.g. buffer, salt, temperature and pH) in the presence of nucleotides and an agent for nucleic acid polymerization, such as DNA
10 dependent or RNA dependent polymerase. A primer must be sufficiently long to prime the synthesis of extension products in the presence of an agent for polymerization. A typical primer contains at least about 10 nucleotides in length of a sequence substantially complementary (P1) or homologues (P2) to the target sequence, but somewhat longer primers are preferred. Usually primers contain
15 about 15-26 nucleotides but longer primers, up to 35 nucleotides may also be employed.

Normally a set of primers will consist of at least two primers, one 'upstream' and one 'downstream' primer which together define the amplificate (the sequence that will be amplified using said primers).

20 An upstream primer (P1) will always contain a sequence substantially complementary to the target sequence to which it may anneal. A downstream primer (P2) will contain a sequence substantially homologous to the target sequence.

A primer may, optionally, also comprise a promoter sequence. The term "promoter sequence" defines a region of a nucleic acid sequence that is specifically
25 recognized by an RNA polymerase that binds to a recognized sequence and initiates the process of transcription by which an RNA transcript is produced. In principle any promoter sequence may be employed for which there is a known and available polymerase that is capable of recognizing the initiation sequence. Known and useful promoters are those that are recognized by certain bacteriophage RNA polymerases
30 such as bacteriophage T3, T7 or SP6.

It is understood that a nucleic acid primer consisting of the sequences of the present invention may contain minor deletions, additions and/or substitutions of nucleic acid bases, to the extent that such alterations do not negatively affect the yield or product obtained to a significant degree.
35

Various techniques for amplifying nucleic acids are known in the art. One example of a technique for the amplification of a DNA target segment is the so-called "polymerase chain reaction" (PCR). With the PCR technique the copy number of a particular target segment is increased exponentially with a number of
40 cycles. In each cycle a DNA primer is annealed to the 3' side of each strand of the double stranded DNA-target sequence. The primers are extended with a DNA

polymerase in the presence of the various mononucleotides. The extension products are rendered single stranded by thermal denaturation and each strand can serve as a template for primer annealing and subsequent elongation in a following cycle. The PCR method has been described in *Saiki et al.* (Science 230, 135 (1985)) and in European Patent nos. EP 0 200 362 and EP 0 201 184.

Another technique for the amplification of nucleic acid is the so-called transcription based amplification system (TAS). TAS employs an RNA-transcript-production step from a DNA, synthesized to incorporate a segment of the target sequence and a promoter, to enable transcription from the segment of a RNA with the sequence complementary to that of the target. Multiple cycles can be carried out as the RNA made in the transcription step can serve as template for making similarly transcribable DNA, which in turn, can be transcribed to yield additional RNA. The TAS method is described in International Patent Appl. no. WO 88/10315.

Yet another method for the amplification of nucleic acid is the nucleic acid sequence based amplification process ("NASBA®") as described in European Patent No. 0 329 822 B1. Like TAS, NASBA® includes a RNA-transcript production step using T7 RNA polymerase to transcribe multiple copies of RNA from a DNA template including a T7 promoter sequence.

It is contemplated that amplification may involve another process either in addition to or in place of the one generally illustrated in Figure 1. These other processes, of which some are described above, using the oligonucleotides according to the present invention fall within the scope of the present invention.

There is, *a priori*, no known method of prediction the usefulness of a primer pair in an amplification system. Knowledge of the chemical composition and structure of primers is not sufficient to allow prediction of their usefulness in an amplification system, including NASBA®.

An object of the present invention is directed to primer combinations, P1 (for instance P1 includes a T7 RNA polymerase promoter sequence (small characters)) and P2, that are useful for the amplification of a *M. pneumoniae* 16S rRNA sequence by NASBA®.

P1 (OT2157): 5' aat tct aat acg act cac tat agg gAG GTC CTT TCA ACT TTG ATT CA 3'

P2 (OT2156): 5' GAT CCT GGC TCA GGA TTA A 3'

P1 primer (OT2157), initially hybridizes to the RNA template and serves as a primer for reverse transcriptase to initiate first strand cDNA synthesis. P2 primer (OT2156), which consists of a single region that hybridizes to the complementary

strand of the RNA sequence to be amplified. After second strand synthesis, the complete cDNA contains the T7 RNA polymerase promoter site from the P1 primer. T7 RNA polymerase can now bind and initiate RNA synthesis, which is the amplification phase of the NASBA® reaction.

5

Once the RNA is amplified using a primer pair as set forth above, detection of the amplicate or amplicon can be done using specific probes.

A probe that may be used for the detection of the amplicate generated using this primer set may comprise an oligonucleotide, 10-35 nucleotides in length comprising, at least a fragment of 10 nucleotides, of a sequence selected from the group consisting of:

10

5' TCG ATC GGA AGT AGT AAT ACT TTA 3' (OT2207)

5' TCG ATC GAA AGT AGT AAT ACT TTA 3' (pd95)

15

Probes comprising said sequence are also part of the present invention.

These preferred type-specific probes are complementary to a variable region (V1) of 16S ribosomal RNA. Surprisingly is found that these probes are type-specific. OT2207-probe is *M. pneumoniae* type 1 specific and pd 95-probe is *M. pneumoniae* type-2 specific.

20

The nucleotide sequence of the two *M. pneumoniae* strains revealed a one-point difference at the 16S rRNA level between *M. pneumoniae* type 1 and 2. This one-base difference in the variable region V1, consisted in a switch of the guanine base in *M. pneumoniae* type 1 by an adenine base in *M. pneumoniae* type 2 and was located at position 71 (numbering according to Weisburg *et al.*, J. Bacteriol. 171:6455-6467 (1989)).

25

The present invention is not limited to the above-noted probes, which are only presented as type-specific examples. General (non-type-specific) Mycoplasmal 16S rRNA probes are known and, to the extent that they can bind to the amplified RNA, are included as useful in the detection of *M. pneumoniae* infection.

30

An oligonucleotide sequence used as detection-probe may be labeled with a detectable moiety. Various labeling moieties are known in the art. Said moiety may, for example, either be a radioactive compound, a detectable enzyme (e.g. horse radish peroxidase (HRP)) or any other moiety capable of generating a detectable signal such as a colorimetric, fluorescent, chemiluminescent or electrochemiluminescent signal.

35

Such a detection probe can be used in a process for detection and typing of *M. pneumoniae* RNA, preferably 16 S rRNA, extracted directly from the sample and/or extracted from cultivated (sample-borne) *M. pneumoniae*.

5 An object of the present invention is directed to a process for amplifying a target ribonucleic acid in RNA of *Mycoplasma pneumoniae*, comprising the steps of:

(a) hybridizing to single-stranded ribosomal RNA a primer containing a polymerase promoter nucleic acid sequence and the sequence (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3';

10 (b) using reverse transcriptase to extend said first primer to thereby obtain an RNA-DNA hybrid, and creating a single-stranded DNA from said RNA-DNA hybrid;

(c) hybridizing to said single-stranded DNA a second primer consisting of the nucleic acid sequence (P2) 5' GAT CCT GGC TCA GGA TTA A 3' and extending said second primer to thereby obtain a double-stranded DNA template containing a functional polymerase promoter; and

15 (d) using RNA polymerase to generate multiple copies of single-stranded RNA using said double-stranded DNA of step (c) as a template.

20 A preferred embodiment of the present invention is directed to the above process wherein the single stranded RNA obtained in step (d) acts as a template for the synthesis of (partial) double-stranded DNA by steps (a) through (c) with the primers annealing in reversed order, thereby establishing a cyclic phase of amplification (see Figure 1).

25

Another preferred embodiment of the present invention is directed to the above process wherein step (b) RNase H activity is used to create single-stranded DNA from the RNA-DNA hybrid.

30 Another object of the present invention is directed to a method for the detection of *Mycoplasma pneumoniae* in a sample, comprising the steps of:

(a) hybridizing to the single-stranded ribosomal RNA a primer containing a polymerase promoter nucleic acid sequence and the sequence (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3';

35 (b) using reverse transcriptase to extend said first primer to thereby obtain an RNA-DNA hybrid, and creating a single-stranded DNA from said RNA-DNA hybrid;

(c) hybridizing to said single-stranded DNA a second primer consisting essentially of the nucleic acid sequence (P2) 5' GAT CCT GGC TCA GGA TTA A 3' and extending said second primer to thereby obtain a double-stranded DNA template containing a functional polymerase promoter;

40

(d) using RNA polymerase to generate multiple copies of single-stranded RNA using said double-stranded DNA of step (c) as a template.

(e) hybridizing the RNA so amplified with the sequence specific oligonucleotide probe; and

5 (f) detecting hybrids formed between said nucleic acid and said probe.

A preferred embodiment is directed to the above method wherein the sequence specific oligonucleotide probe of step (e) is type-specific.

10 Another preferred embodiment is directed to the above method wherein said type-specific oligonucleotide probe being 10-35 nucleotides in length and comprising, at least a fragment of 10 nucleotides of a sequence consisting of:

5' TCG ATC GGA AGT AGT AAT ACT TTA 3' (type 1), or

15 5' TCG ATC GAA AGT AGT AAT ACT TTA 3' (type 2), or its complementary sequence.

Another object of the present invention is directed to a method for the detection of *Mycoplasma pneumoniae* in a sample, comprising the steps of:

20 (a) hybridizing RNA extracted from the sample and/or from cultivated sample-borne *M. pneumoniae* with one or more sequence specific probes; and

(b) detecting hybrids formed between said nucleic acid and said probe(s).

25 Test kits for the detection of *M. pneumoniae* in clinical samples are also part of the present invention. A test kit according to the invention may comprise a set of primers according to the invention and a probe according to the invention. Such a test kit may additionally comprise suitable amplification reagents such as DNA and or RNA polymerases and mononucleotides.

30 An object of the present invention is directed to a test kit for detecting and optionally identifying *Mycoplasma pneumoniae* in a sample, wherein the kit comprises a pair of primers, wherein the first primer comprises an RNA polymerase promoter sequence and a hybridizing sequence being 10-35 nucleotides in length and comprising at least a fragment of 10 nucleotides of a sequence consisting of (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3', and the second primer sequence being 35 10-35 nucleotides in length and comprising at least a fragment of 10 nucleotides of a sequence consisting of (P2) 5' GAT CCT GGC TCA GGA TTA A 3'.

40 Such a test kit may further comprise an oligonucleotide probe containing a nucleic acid sequence capable of hybridizing to the region of the RNA amplified using the first primer and the second primer.

A preferred object of the present invention is directed to a test kit typing *Mycoplasma pneumoniae* strains in a sample, wherein the kit comprises a pair of primers, wherein the first primer comprises an RNA polymerase promoter and a hybridizing sequence being 10-35 nucleotides in length and comprising at least a
5 fragment of 10 nucleotides of a sequence consisting of (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3', and the second primer sequence being 10-35 nucleotides in length and comprising at least a fragment of 10 nucleotides of a sequence consisting of (P2) 5' GAT CCT GGC TCA GGA TTA A 3', and further comprising an oligonucleotide probe being 10-35 nucleotides in length and comprising at least a
10 fragment of 10 nucleotides of a sequence consisting of 5' TCG ATC GGA AGT AGT AAT ACT TTA 3' (type 1) or 5' TCG ATC GAA AGT AGT AAT ACT TTA 3' (type 2) which are capable of hybridizing to the region of the RNA amplified using the first primer and the second primer.

15 Another object of the present invention is directed to a test kit for detecting of *Mycoplasma pneumoniae* in a sample, wherein said test kit comprises:
one or more sequence specific oligonucleotide probes capable of hybridizing to RNA extracted from the sample and/or from cultivated sample-borne *M. pneumoniae*.

20

The invention is further exemplified by the following example.

EXAMPLES:

25

Example 1: Analysis of *M. pneumoniae* NA in clinical samples.

Bacterial strains

30 The 24 *M. pneumoniae* strains analyzed in this study are listed in Table 1. Fifteen strains were isolated from clinical samples in the Microbiology laboratory, University Hospital UIA, Belgium, during a study of respiratory tract infections in children between October 1, 1991 and March 31, 1992 and between October 1, 1992 and March 31, 1993 (Ieven *et al.*, abstr. J127, p.116. *In* Program and
35 abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington (1994)).

In this study, nasopharyngeal aspirates of pediatric patients were examined for the presence of *M. pneumoniae* and respiratory viruses. The presence of *M. pneumoniae* was detected by culture and a PCR amplifying part of the P1 gene (Ursi
40 *et al.*, Acta Pathol. Microbiol. Immunol. Scand. **100**:635-639 (1992)). The strains were isolated from 15 outpatients epidemiologically unrelated to each other. Three

strains were isolated in the United Kingdom between 1983 and 1986 (M 15/83, M 414/86, and M 510/86) and three strains in The Netherlands between 1970 and 1987 (P 635, P 71, and P 84). Three *M. pneumoniae* reference strains (FH, MAC, and PI 1428) were also included.

5 All *M. pneumoniae* strains were cultured in spiroplasma (SP4) broth as described previously (Ursi *et al.*, J. Clin. Microbiol. **32**:2873-2875 (1994)).

Nucleic acid isolation

10 Lysis and total nucleic acid isolation was performed using guanidinium thiocyanate-mediated cell lysis and adsorption of nucleic acid to silica particles (Boom *et al.*, J. of Clin. Microbiology **28**, 495-503 (1990)).

100 μ l of SP4 broth with the bacteria was added to 900 μ l of a guanidinium thiocyanate (GuSCN) lysis solution (5.25 M GuSCN, 50 mM Tris-HCl, pH 6.4, 20 mM EDTA, 1.3% (w/v) Triton X-100) and mixed vigorously for rapid lysis.

15 Subsequently, 70 μ l of Hydrochloric acid-activated silicium dioxide particles [size-selected suspension of 1 mg/ml in 0.1 M Hydrochloric acid (Sigma); see ref. Boom *et al.*, 1990] were added and the suspension was incubated during 10 minutes at room temperature with regular vortexing. Nucleic acid bound to the silica was spun down by centrifugation. Pelleted silica particles were washed twice with 1 ml
20 GuSCN wash buffer [50 mM Tris-Hydrochloric acid (pH 6.4); 5.25 M Guanidinium thiocyanate], followed by two washing steps with 1 ml 70% ethanol and a single washing step with 1 ml acetone. After each washing step, the suspension was briefly centrifuged and the silica pellet was resuspended in the next washing solution by thorough mixing. After removal of the acetone, the silica particles were dried by
25 incubation at 56°C in a heating block during 10 minutes. Nucleic acid was eluted from the silica particles by incubation in 100 μ l distilled water (RNase- / DNase-free H₂O) at 56°C during 10 minutes. Finally, the silica particles were spun down again and the supernatant was carefully pipetted into fresh reaction tubes avoiding any carry-over of silica. Extracted nucleic acid samples were stored at -70°C until
30 use.

Primers and probes

The primers and probes used are listed in Table 2.

Synthesis of primers and probes:

35 All oligonucleotide primers and probes were synthesized on a PCR-MATE 391 DNA synthesizer (Applied Biosystems) using phosphoramidite biochemistry. Oligonucleotides for ELGA detection (see below) were synthesized with a 5'-amino link (Aminolink 2; Applied Biosystems) for subsequent coupling of Horse Radish Peroxidase (HRP).

40 Amplification primers were purified by electrophoretically separating the crude oligonucleotide solutions over a 20% polyacrylamide/7M Urea slabgel and

subsequent elution of the full-length oligonucleotide from the corresponding gel band. After elution from the gel slices and concentration by ethanol precipitation, primers were dissolved in Milli-Q water and concentrations determined by OD(260 nm) measurement.

5 Detection probes were conjugated with HRP (Boehringer) by coupling the enzyme to the amino link of the oligonucleotide using the cross-linking reagents SDPD (Pharmacia) and EMCS (Fluka). Unbound HRP was removed over a Qiagen Tip-100 column (Qiagen). The HRP-labeled oligonucleotides were purified by polyacrylamide gel electrophoresis and subsequent elution of the HRP-oligonucleotides from the gel slices by overnight incubation in water. The amount of HRP-conjugated oligonucleotide was calculated from OD(260nm) and OD(400 nm) measurement. The solutions were stored at -70°C.

Selection of primers and probes:

15 The primers and probes used (Table 2) were chosen from a 16S rRNA sequence alignment of *Mycoplasma* species (Weisburg *et al.*, J. Bacteriol. 171:6455-6467 (1989)). Forward primer OT2156 was chosen from a highly conserved region, while reverse primer OT2157 was localized on the variable region V2 (Neefs *et al.*, Nucleic Acids Res. 18 suppl:2237-2317 (1990)). These primers were calculated to be 190 nucleotides apart. This stretch contains a sequence specific for *M. pneumoniae*. Type-specific probes complementary to the variable region V1 of the 16S rRNA gene were synthesized for the identification of *M. pneumoniae* type 1 (OT2207) and *M. pneumoniae* type 2 (pd 95).

NASBA® amplification

25 The NASBA® reactions were performed as described by Kievits *et al.* (J. Virol. Methods. 35:273-286 (1991)) with some modifications. The final volume of the reaction mixture was 20 µl. First, to a 10-µl volume of prereaction mixture consisting of 40 mM Tris-HCl, pH 8.5, 12 mM MgCl₂, 70 mM KCl, 5 mM DTT, 1 mM of each dNTP, 2 mM ATP, 2 mM CTP, 2 mM UTP, 1.5 mM GTP, 0.5 mM ITP, 15% (v/v) DMSO, 0.2 µM of each primer, was added. After addition of 5 µl of target RNA the tubes were incubated for 5 min at 65°C to uncoil the tertiary and secondary structures of the 16S rRNA. The reaction mixtures were then transferred to 41°C for 5 min. Finally, 5 µl of enzyme mix was added, containing 1.5 M sorbitol, 2.1 µg bovine serum albumin (Boehringer Mannheim), 32 U T7 RNA polymerase (Pharmacia), 6.4 U AMV-RT (Seikagaku), 0.08 U RNase-H (Pharmacia), resulting in a final volume of 20 µl. Isothermal amplification of the target RNA was performed at 41°C for 1.5 h. Reaction mixtures in which the target nucleic acid was replaced by 5 µl RNase- / DNase-free H₂O, served as negative controls. The amplification products were processed immediately by the ELGA.

Analysis of NASBA®-amplified products (ELGA)

NASBA® products were identified by a rapid, non-radioactive, 'in-solution' hybridization assay (ELGA) with species-specific oligonucleotide probes 5'-labelled with horse-radish peroxidase (HRP). Since the NASBA® products are single-stranded RNA there is no need for prior denaturation. After hybridization, excess non-hybridized ELGA probes were separated from the homologous hybridized product by vertical gel electrophoresis and visualized in the acrylamide gel by incubating the gel in the substrate solution for HRP. Because of its lower mobility, the homologous hybridized product migrates in the gel above the free ELGA probe.

One μl of the NASBA® reaction product was mixed with 4 μl hybridization solution (final concentration of this reaction mix was 1x SSC (0.15 M NaCl, 0.015 M sodium citrate), 0.01% bromophenol blue, 0.01% xylene cyanol and 6.10^{11} molecules of HRP-labelled probes) and incubated at 50°C for 15 min. Hybridization reaction mixtures (2.5 μl) were then applied on a 7% acrylamide gel, containing 0.04% (w/v) dextran sulphate. After electrophoresis, the gel was incubated in 40 ml of substrate solution (0.125 mg of 3,3',5,5'-tetramethylbenzidine per ml, 0.003% (v/v) H_2O_2 in 0.1 M sodium citrate, pH 5.6) for approximately 5 min at room temperature. The gel was fixed by incubation in 50% (v/v) methanol overnight at room temperature.

Sequencing of the NASBA® amplicons

For the sequencing of the NASBA® amplicons (- RNA) the template was separated from the primers and free nucleotides. This was done by purifying 10 μl of amplicon over a QIAquick-spin column (QIAquick-spin, PCR Purification Kit (250), Qiagen), according to the manufacturer's instructions. For nucleotide sequence analysis, 1/10 of the purified sample was used, as well as 1.6 pmol of 5'-end ^{32}P -labelled primer 2 (OT2156, Table 2). Nucleotide sequence analysis was performed with the dideoxynucleotide-terminated chain elongation method, modified for the use of RT and RNA templates (Lane *et al.*, Proc. Natl. Acad. Sci. USA 82:6955-6959 (1985))

TABLE 1. *M. pneumoniae* strains used in this study

| Nr. | Strain | Source ^a | Year and source of isolation | Clinical picture | Type ^b |
|-----|------------------------|---------------------|------------------------------|-----------------------------------------------|-------------------|
| 1 | FH (NCTC 10119) | NCTC | 1959; not specified | Pneumonia | 2 |
| 2 | M 15/83 | NCTC | 1983; sputum | Pneumonia | 1 |
| 3 | M414/86 | NCTC | 1986; sputum | Pneumonia | 1 |
| 4 | M510/86 | NCTC | 1986; sputum | Pneumonia | 1 |
| 5 | P635 | RIVM | 1970's; throat swab | Pneumonia | 2 |
| 6 | P71 | RIVM | 1987; BAL ^c | Pneumonia | 1 |
| 7 | P84 | RIVM | 1973; not specified | Pneumonia | 2 |
| 8 | M2117350 | UZA | 1992; NPA ^d | Acute bronchitis | 1 |
| 9 | M2107084 | UZA | 1992; throat swab | Acute bronchitis Erythema multiforma | 1 |
| 10 | M2117245 | UZA | 1992; NPA | URTI ^e | 1 |
| 11 | M2107079 | UZA | 1992; sputum | Acute lobar pneumonia | 1 |
| 12 | M2107374 | UZA | 1992; NPA | Acute lobar pneumonia | 1 |
| 13 | M2117235 | UZA | 1992; throat swab | Acute lobar pneumonia | 1 |
| 14 | M2117430 | UZA | 1992; NPA | Acute bronchitis | 1 |
| 15 | M3057031 | UZA | 1993; NPA | Acute bronchitis | 1 |
| 16 | M3037439 | UZA | 1993; NPA | Acute bronchopneumonia | 1 |
| 17 | 21C86 | UZA | 1992; NPA | Acute bronchitis | 1 |
| 18 | 21K11 | UZA | 1992; NPA | Acute bronchopneumonia | 2 |
| 19 | 21K33 | UZA | 1992; NPA | Acute bronchopneumonia | 1 |
| 20 | 21G93 | UZA | 1992; NPA | Acute bronchopneumonia | 1 |
| 21 | 21I105 | UZA | 1992; sputum | Acute bronchopneumonia Exanthema | 1 |
| 22 | DEV | UZA | 1991; NPA | Acute bronchopneumonia Erythema multiforma | 1 |
| 23 | PI1428 (ATCC 29085) | ATCC | 1964; throat swab | Pneumonia | 1 |
| 24 | MAC (ATCC 15492) | ATCC | 1944; lung tissue | Not specified | 2 |

^a Abbreviations: NCTC, National Collection of Type Cultures, Central Public Health Laboratory, London, United Kingdom; ATCC, American Type Culture Collection, Rockville, Md.; RIVM, Rijksinstituut voor Volksgezondheid en Milieuhygiëne, Bilthoven, The Netherlands; UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium.

^b Typing results were obtained with NASBA as described in this study.

^c BAL, bronchoalveolar lavage.

^d NPA, nasopharyngeal aspirate.

^e URTI, upper respiratory tract infection.


TABLE 2. Sequences of primers and probes used in amplification of 16S rRNA

| Oligo | Sequence |
|----------------|-------------------------------------------------------------------------|
| P1 OT2157 | 5' AAT TCT AAT ACG ACT CAC TAT AGG GAG GTC CTT TCA ACT TTG ATT CA 3' |
| P2 OT2156 | 5' GAT CCT GGC TCA GGA TTA A 3' |
| type 1: OT2207 | 5' TCG ATC GGA AGT AGT AAT ACT TTA 3' |
| type 2: pd 95 | 5' TCG ATC GAA AGT AGT AAT ACT TTA 3' |

5

Brief description of the figures:

Figure 1: The NASBA® amplification principle.



15 Figure 2: The specificity of NASBA® in combination with ELGA for typing a collection of 24 *M. pneumoniae* strains is shown.

Primers OT2156 and OT2157 were used for NASBA® amplification. Probes OT2207 and pd 95 were used for typing the 24 *M. pneumoniae* strains.

20 Probe OT2207 (specific for type 1) hybridized with amplified RNA from 19 of the 24 strains (Fig. 2a) and probe pd 95 (specific for type 2) hybridized with amplified RNA from the remaining 5 strains (Fig. 2b) (Table 1).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT:

(A) NAME: AKZO NOBEL N.V.

(B) STREET: Velperweg 76

(C) CITY: Arnhem

10

(E) COUNTRY: The Netherlands

(F) POSTAL CODE (ZIP): 6824 BM

(ii) TITLE OF INVENTION: Primers and probes for the amplification,
detection and typing of *Mycoplasma pneumoniae*

15

(iii) NUMBER OF SEQUENCES: 4

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

20

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

25

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

(B) TYPE: nucleic acid

30

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA to rRNA

35

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycoplasma pneumoniae*

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

AGGTCCTTTC AACTTTGATT CA

22

(2) INFORMATION FOR SEQ ID NO: 2:

5 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 19 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

10

(ii) MOLECULE TYPE: cDNA to rRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycoplasma pneumoniae*

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

20 GATCCTGGCT CAGGATTA

19

(2) INFORMATION FOR SEQ ID NO: 3:

25 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

30

(ii) MOLECULE TYPE: cDNA to rRNA

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycoplasma pneumoniae*

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

40 TCGATCGGAA GTAGTAATAC TTTA

24

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

5 (C) STRANDEDNESS: single

(D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: cDNA to rRNA

10 (vi) ORIGINAL SOURCE:

(A) ORGANISM: *Mycoplasma pneumoniae*

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TCGATCGAAA GTAGTAATAC TTTA

24

CLAIMS:

1. An oligonucleotide, 10-35 nucleotides in length comprising, at least a fragment of 10 nucleotides of a sequence selected from the group consisting of:
5 (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3',
(P2) 5' GAT CCT GGC TCA GGA TTA A 3', or
its complementary sequence.
2. An oligonucleotide according to claim 1, operably linked to a promoter
10 nucleic acid sequence.
3. A pair of oligonucleotide primers for the amplification of *Mycoplasma pneumoniae* nucleic acid comprising oligonucleotides consisting essentially of the following nucleic acid sequences:
15 (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3',
(P2) 5' GAT CCT GGC TCA GGA TTA A 3', optionally linked to a promoter nucleic acid sequence.
4. A method for amplifying a target ribonucleic acid in RNA of *Mycoplasma pneumoniae*, comprising the steps of:
20 (a) hybridizing to single-stranded ribosomal RNA a primer containing a polymerase promoter nucleic acid sequence and the sequence (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3';
(b) using reverse transcriptase to extend said first primer to thereby obtain an
25 RNA-DNA hybrid, and creating a single-stranded DNA from said RNA-DNA hybrid;
(c) hybridizing to said single-stranded DNA a second primer consisting of the nucleic acid sequence (P2) 5' GAT CCT GGC TCA GGA TTA A 3' and extending said second primer to thereby obtain a double-stranded DNA template
30 containing a functional polymerase promoter; and
(d) using RNA polymerase to generate multiple copies of single-stranded RNA using said double-stranded DNA of step (c) as a template.
5. The method according to claim 4, wherein the single stranded RNA
35 obtained in step (d) acts as a template for the synthesis of partial double-stranded DNA by steps (a) through (c) with the primers annealing in reversed order, thereby establishing a cyclic phase of amplification.
6. The method according to any of claims 4-5, wherein step (b) RNase H
40 activity is used to create single-stranded DNA from the RNA-DNA hybrid.

7. A method for the detection of *Mycoplasma pneumoniae* in a sample, comprising the steps of:

(a) hybridizing to the single-stranded ribosomal RNA a primer containing a polymerase promoter nucleic acid sequence and the sequence (P1) 5' AGG TCC
5 TTT CAA CTT TGA TTC A 3';

(b) using reverse transcriptase to extend said first primer to thereby obtain an RNA-DNA hybrid, and creating a single-stranded DNA from said RNA-DNA hybrid;

10 (c) hybridizing to said single-stranded DNA a second primer consisting essentially of the nucleic acid sequence (P2) 5' GAT CCT GGC TCA GGA TTA A 3' and extending said second primer to thereby obtain a double-stranded DNA template containing a functional polymerase promoter;

(d) using RNA polymerase to generate multiple copies of single-stranded RNA using said double-stranded DNA of step (c) as a template.

15 (e) hybridizing the RNA so amplified with the sequence specific oligonucleotide probe; and

(f) detecting hybrids formed between said nucleic acid and said probe.

20 8. The method according to claim 7, wherein the sequence specific oligonucleotide probe of step (e) is type-specific.

9. The method according to claim 8, wherein said type-specific oligonucleotide probe being 10-35 nucleotides in length and comprising, at least a fragment of 10 nucleotides of a sequence consisting of:

25 5' TCG ATC GGA AGT AGT AAT ACT TTA 3' (type 1), or

5' TCG ATC GAA AGT AGT AAT ACT TTA 3' (type 2), or its complementary sequence.

30 10. A kit for detecting and optionally identifying *Mycoplasma pneumoniae* in a sample, wherein the kit comprises a pair of primers, wherein the first primer comprises an RNA polymerase promoter sequence and a hybridizing sequence being 10-35 nucleotides in length and comprising at least a fragment of 10 nucleotides of a sequence consisting of (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3', and the
35 second primer sequence being 10-35 nucleotides in length and comprising at least a fragment of 10 nucleotides of a sequence consisting of (P2) 5' GAT CCT GGC TCA GGA TTA A 3'.

40 11. The kit according to claim 10, further comprising an oligonucleotide probe containing a nucleic acid sequence capable of hybridizing to the region of the RNA amplified using the first primer and the second primer.

12. A kit for typing *Mycoplasma pneumoniae* strains in a sample, wherein the kit comprises a pair of primers, wherein the first primer comprises an RNA polymerase promoter and a hybridizing sequence being 10-35 nucleotides in length and comprising at least a fragment of 10 nucleotides of a sequence consisting of (P1) 5' AGG TCC TTT CAA CTT TGA TTC A 3', and the second primer sequence being 10-35 nucleotides in length and comprising at least a fragment of 10 nucleotides of a sequence consisting of (P2) 5' GAT CCT GGC TCA GGA TTA A 3', and further comprising an oligonucleotide probe being 10-35 nucleotides in length and comprising at least a fragment of 10 nucleotides of a sequence consisting of 5' TCG ATC GGA AGT AGT AAT ACT TTA 3' (type 1) or 5' TCG ATC GAA AGT AGT AAT ACT TTA 3' (type 2) which are capable of hybridizing to the region of the RNA amplified using the first primer and the second primer.

INTERNATIONAL SEARCH REPORT

International Application No
PC1/EP 97/00911

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12Q1/68 C07H21/04 C12P19/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X | INFECTIOUS DISEASES, vol. 69, no. 6, June 1995, pages 723-8, XP000575786 OKAZAKI N ET AL: "Detection of mycoplasma pneumoniae from throat swab by polymerase chain reaction" --- see abstract | 1 |
| Y | --- see abstract | 2-7, 10-12 |
| X | EUROPEAN JOURNAL CLINICAL MICROBIOL. INFECT. DIS., vol. 15, no. 1, January 1996, pages 38-44, XP000576278 JACOBS E ET AL: "Are outbreaks and sporadic respiratory infections by mycoplasma pneumoniae due to two distinct subtypes?" see page 41; figures FIG.1 --- -/-- | 1,8,9 |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 June 1997

Date of mailing of the international search report

23. 06. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

International Application No

PC1/EP 97/00911

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X | EUROPEAN JOURNAL CLIN. MICROBIOL. INFECT. DIS, vol. 13, no. 5, May 1994, pages 401-5, XP000576280 VAN KUPPEVELD F ET AL: "16S rRNA based polymerase chain reaction compared with culture and serological methods for the diagnosis of mycoplasma pneumoniae infection" see the whole document --- | 1 |
| X | JOURNAL OF CLINICAL MICROBIOLOGY, vol. 32, no. 11, November 1994, pages 2873-5, XP000576271 URSI D ET AL: "Typing of mycoplasma pneumoniae by PCR mediated fingerprinting" see the whole document --- | 1 |
| A | | 8,9 |
| Y | JOURNAL OF VIROLOGICAL METHODS, vol. 35, 1991, pages 273-86, XP000576430 KIEVITS T ET AL: "NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection" see figure 2 --- | 2-7, 10-12 |
| X | JOURNAL CLINICAL MICROBIOLOGY, vol. 32, no. 1, January 1994, pages 11-16, XP000576264 TJHIE J ET AL: "Direct PCR enables detection of mycoplasma pneumoniae in patients with respiratory tract infections" see the whole document --- | 1 |
| Y | | 2-7, 10-12 |
| | ----- | |